Zhaohui Feng

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6660311/publications.pdf

Version: 2024-02-01

7,796	101543	175258
citations	h-index	g-index
55	55	11118
docs citations	times ranked	citing authors
		7,796 36 citations h-index 55 55

#	Article	IF	CITATIONS
1	The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8204-8209.	7.1	1,100
2	Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7455-7460.	7.1	697
3	The Regulation of AMPK \hat{I}^21 , TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways. Cancer Research, 2007, 67, 3043-3053.	0.9	546
4	p53 regulates maternal reproduction through LIF. Nature, 2007, 450, 721-724.	27.8	387
5	Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16259-16264.	7.1	342
6	Tumour-associated mutant p53 drives the Warburg effect. Nature Communications, 2013, 4, 2935.	12.8	329
7	The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends in Cell Biology, 2010, 20, 427-434.	7.9	316
8	Negative Regulation of Tumor Suppressor p53 by MicroRNA miR-504. Molecular Cell, 2010, 38, 689-699.	9.7	285
9	Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16633-16638.	7.1	243
10	Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy. Journal of Molecular Biology, 2017, 429, 1595-1606.	4.2	219
11	Tumor suppressor p53 and its mutants in cancer metabolism. Cancer Letters, 2015, 356, 197-203.	7.2	210
12	Tumor suppressor p53 meets microRNAs. Journal of Molecular Cell Biology, 2011, 3, 44-50.	3.3	206
13	p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal Compartment. Cold Spring Harbor Perspectives in Biology, 2010, 2, a001057-a001057.	5 . 5	192
14	Single-nucleotide polymorphisms in the p53 pathway regulate fertility in humans. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9761-9766.	7.1	175
15	Tumor suppressor p53 and metabolism. Journal of Molecular Cell Biology, 2019, 11, 284-292.	3.3	174
16	Chronic restraint stress attenuates p53 function and promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7013-7018.	7.1	156
17	LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nature Communications, 2014, 5, 5218.	12.8	152
18	Parkin targets HIF- $1\hat{l}_{\pm}$ for ubiquitination and degradation to inhibit breast tumor progression. Nature Communications, 2017, 8, 1823.	12.8	151

#	Article	IF	CITATIONS
19	Gain-of-function mutant p53 in cancer progression and therapy. Journal of Molecular Cell Biology, 2020, 12, 674-687.	3.3	146
20	The Regulation of Multiple p53 Stress Responses is Mediated through MDM2. Genes and Cancer, 2012, 3, 199-208.	1.9	128
21	LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget, 2014, 5, 788-801.	1.8	128
22	The Regulation of Ferroptosis by Tumor Suppressor p53 and its Pathway. International Journal of Molecular Sciences, 2020, 21, 8387.	4.1	122
23	MicroRNA Control of p53. Journal of Cellular Biochemistry, 2017, 118, 7-14.	2.6	115
24	The tumor suppressor p53: Cancer and aging. Cell Cycle, 2008, 7, 842-847.	2.6	106
25	The regulation of cellular metabolism by tumor suppressor p53. Cell and Bioscience, 2013, 3, 9.	4.8	101
26	Cullin3–KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes and Development, 2016, 30, 1956-1970.	5.9	100
27	Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis. Nature Communications, 2013, 4, 2996.	12.8	94
28	Tumor suppressor p53 negatively regulates glycolysis stimulated by hypoxia through its target RRAD. Oncotarget, 2014, 5, 5535-5546.	1.8	81
29	Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. ELife, 2016, 5, e10727.	6.0	79
30	Regulation of female reproduction by p53 and its family members. FASEB Journal, 2011, 25, 2245-2255.	0.5	71
31	The Regulation of Aging and Longevity: A New and Complex Role of p53. Genes and Cancer, 2011, 2, 443-452.	1.9	70
32	BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function. ELife, 2015, $4, .$	6.0	61
33	MicroRNA-339-5p inhibits colorectal tumorigenesis through regulation of the MDM2/p53 signaling. Oncotarget, 2014, 5, 9106-9117.	1.8	58
34	Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression. Journal of Clinical Investigation, 2020, 130, 3253-3269.	8.2	51
35	microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis. Oncotarget, 2016, 7, 8783-8796.	1.8	36
36	A polymorphism in the tumor suppressor p53 affects aging and longevity in mouse models. ELife, 2018, 7, .	6.0	36

#	Article	IF	CITATIONS
37	Parkinson's diseaseâ€associated protein Parkin: an unusual player in cancer. Cancer Communications, 2018, 38, 1-8.	9.2	36
38	Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression. Genes and Development, 2017, 31, 1641-1654.	5.9	35
39	The emerging role of leukemia inhibitory factor in cancer and therapy. , 2021, 221, 107754.		34
40	Tumor suppressor p53 cross-talks with TRIM family proteins. Genes and Diseases, 2021, 8, 463-474.	3.4	33
41	The Interplay Between Tumor Suppressor p53 and Hypoxia Signaling Pathways in Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 648808.	3.7	33
42	RRAD inhibits the Warburg effect through negative regulation of the NF-κB signaling. Oncotarget, 2015, 6, 14982-14992.	1.8	32
43	A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis. Cell Discovery, 2016, 2, 16039.	6.7	26
44	LIF is essential for ISC function and protects against radiation-induced gastrointestinal syndrome. Cell Death and Disease, 2020, 11, 588.	6.3	22
45	Tumor suppressor p53 regulates intestinal type 2 immunity. Nature Communications, 2021, 12, 3371.	12.8	19
46	Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis. Cell Cycle, 2020, 19, 1338-1351.	2.6	18
47	The regulation of the p53/MDM2 feedback loop by microRNAs. RNA & Disease (Houston, Tex), 2015, 2, e502.	1.0	13
48	EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling. Journal of Molecular Cell Biology, 2020, 12, 477-480.	3.3	9
49	Tumor suppressor p53: new functions of an old protein. Frontiers in Biology, 2011, 6, 58-68.	0.7	7
50	TRIM32 is a novel negative regulator of p53. Molecular and Cellular Oncology, 2015, 2, e970951.	0.7	7
51	Leukemia inhibitory factor drives glucose metabolic reprogramming to promote breast tumorigenesis. Cell Death and Disease, 2022, 13, 370.	6.3	5
52	The role of p53 in reproduction, an unexpected function for a tumor suppressor. Journal of Molecular Cell Biology, 2019, 11, 624-627.	3.3	3
53	Hypothermia Is a Potential New Therapy for a Subset of Tumors with Mutant p53. Cancer Research, 2021, 81, 3762-3763.	0.9	1
54	microRNAs and tumor suppressor p53 regulation. , 2022, , 37-46.		0